Kirin Holdings Company (2503) Q2 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2024 earnings summary
19 Aug, 2026Executive summary
Q2 FY2024 revenue rose 12.9% year-over-year to ¥1,095.8 billion, with normalized operating profit up 23.8% to ¥93.1 billion and profit attributable to owners up 78.9% to ¥57.2 billion, driven by strong overseas businesses and favorable foreign exchange rates.
Operating profit more than doubled year-over-year, supported by strong segment performance and lower other operating expenses.
All four business segments contributed to profit growth, with notable gains in Non-Alcoholic Beverages and Pharmaceuticals.
Comprehensive income surged 68.3% to ¥226.6 billion, reflecting significant foreign currency translation gains.
Upward revision of full-year revenue forecast, maintaining initial normalized OP target despite higher corporate tax expenses.
Financial highlights
Q2 FY2024 revenue: ¥1,095.8bn, up 12.9% YoY; normalized OP: ¥93.1bn, up 23.8%; profit before tax: ¥108.5bn (+90.2% YoY); profit attributable to owners: ¥57.2bn (+78.9% YoY).
Normalized EPS: ¥81, up 11.0% YoY; normalized EBITDA rose 18.1% to ¥139.5bn.
Q2 segment revenue: Alcoholic Beverages ¥512.5bn (+6.6%), Non-Alcoholic Beverages ¥270.0bn (+12.0%), Pharmaceuticals ¥232.8bn (+17.0%), Health Science ¥69.6bn (+92.2%).
Q2 segment normalized OP: Alcoholic Beverages ¥50.3bn (+11.9%), Non-Alcoholic Beverages ¥30.1bn (+31.0%), Pharmaceuticals ¥41.1bn (+13.7%), Health Science -¥1.6bn (improved from -¥4.4bn).
Gross profit increased 15.4% YoY to ¥501.7bn, with gross margin improvement.
Outlook and guidance
FY2024 revenue forecast revised upward to ¥2,300.0bn (+7.8% YoY); normalized OP target maintained at ¥202.0bn; profit attributable to owners forecast at ¥114.0bn.
Normalized EPS forecast revised to ¥162; basic EPS for the year forecast at ¥140.76 due to higher tax expense; dividend per share unchanged at ¥71.
ROIC forecast at 6.8% (down from 8.0% in FY23); guidance revision reflects higher revenue but lower profit expectations due to increased tax and lower other income.
Latest events from Kirin Holdings Company
- Strong profit growth, asset sale, and new acquisition highlight a robust Q2 FY2026.2503
Q2 2026 - Q1 FY2026 saw robust profit growth and margin improvement across all major segments.2503
Q1 2026 - Targets high single-digit EPS growth, ROIC ≥10%, and 3 trillion yen market cap by 2035.2503
Investor presentation - Profit more than doubled, Health Science turned profitable, and major portfolio moves were made.2503
Q4 2025 - Profit and revenue up, FANCL fully consolidated, Health Science segment surges.2503
Q3 2025 - Revenue rose 3.7% YoY, but profit and EPS fell on restructuring and FX impacts.2503
Q2 2025 - Revenue and operating profit rose, but net profit dropped on FANCL acquisition loss.2503
Q3 2024 - Revenue and profit grew, but net income fell on FX and equity changes from FANCL buyout.2503
Q1 2025 - FY2025 profit is set to rebound sharply, driven by Health Science and Alcoholic Beverages.2503
Q4 2024